Daily FNArena News

Baby Bunting has confidently reiterated earnings assumptions for FY20, with an expanded gross margin being the main surprise in a detailed trading update at the AGM.

EclipX Group is reverting to focus on its core fleet and novated leasing businesses, and interest in the company is only expected to grow.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. NextDC has defied the critics so far, with sales in excess of what can be delivered and the next two years of operating earnings growth supported by existing contracts.

Michael Gable of Fairmont Equities suggest the long downturn in the Domino’s Pizza share price may have come to an end.

As a record low cash rate prevails, amid weak consumer and business sentiment and only muted improvements in housing activity, Australia’s major banks are being squeezed mercilessly.

A new report reveals what investors may already know, that “fees make all the difference” to final outcomes for superannuation members’ retirement savings, with many funds struggling to generate returns strong enough to cover the negative impact of high investment fees.

A new specialty female oral contraceptive will grace the portfolio of Mayne Pharma, providing a substantial growth opportunity in the medium-long term.

The Chartist suggests recent consolidation for the iron ore price implies risk remains to the upside.

The New Criterion’s Tim Boreham notes massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world’s foremost pain medication.

GUD Holdings has successfully coupled cost reductions with price rises and reiterates guidance for modest earnings growth in FY20.